153 related articles for article (PubMed ID: 37225483)
1. HLA-DRB1 Is Associated with Therapeutic Responsiveness in IgG4-related Disease.
Yamamoto M; Tanaka T; Aochi S; Uehara M
Intern Med; 2024 Jan; 63(2):207-211. PubMed ID: 37225483
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
3. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Arthritis Res Ther; 2018 Oct; 20(1):222. PubMed ID: 30285841
[TBL] [Abstract][Full Text] [Related]
4. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
5. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction.
Saeki T; Kawano M; Mizushima I; Yamamoto M; Wada Y; Ubara Y; Nakashima H; Ito T; Yamazaki H; Narita I; Saito T
Clin Exp Nephrol; 2016 Feb; 20(1):87-93. PubMed ID: 26141243
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report.
Otani T; Iwamoto H; Yoshida Y; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hirata S; Sugiyama E; Hattori N
J Asthma; 2022 Dec; 59(12):2395-2401. PubMed ID: 34937495
[No Abstract] [Full Text] [Related]
10. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
11. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
12. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.
Fukui S; Nakai T; Kawaai S; Ikeda Y; Suda M; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
Medicine (Baltimore); 2022 Sep; 101(39):e30932. PubMed ID: 36181016
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease.
Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L
Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297
[TBL] [Abstract][Full Text] [Related]
14. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial.
Wu Q; Chang J; Chen H; Chen Y; Yang H; Fei Y; Zhang P; Zeng X; Zhang F; Zhang W
Int J Rheum Dis; 2017 May; 20(5):639-646. PubMed ID: 28556584
[TBL] [Abstract][Full Text] [Related]
15. A CD8α- Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment.
Della-Torre E; Bozzalla-Cassione E; Sciorati C; Ruggiero E; Lanzillotta M; Bonfiglio S; Mattoo H; Perugino CA; Bozzolo E; Rovati L; Arcidiacono PG; Balzano G; Lazarevic D; Bonini C; Falconi M; Stone JH; Dagna L; Pillai S; Manfredi AA
Arthritis Rheumatol; 2018 Jul; 70(7):1133-1143. PubMed ID: 29499100
[TBL] [Abstract][Full Text] [Related]
16. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Shirakashi M; Yoshifuji H; Kodama Y; Chiba T; Yamamoto M; Takahashi H; Uchida K; Okazaki K; Ito T; Kawa S; Yamada K; Kawano M; Hirata S; Tanaka Y; Moriyama M; Nakamura S; Kamisawa T; Matsui S; Tsuboi H; Sumida T; Shibata M; Goto H; Sato Y; Yoshino T; Mimori T
Sci Rep; 2018 Jul; 8(1):10262. PubMed ID: 29980706
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
19. Increased Circulating Th1 and Tfh1 Cell Numbers Are Associated with Disease Activity in Glucocorticoid-Treated Patients with IgG4-Related Disease.
Xia C; Liu C; Liu Y; Long Y; Xu L; Liu C
J Immunol Res; 2020; 2020():3757015. PubMed ID: 33313326
[TBL] [Abstract][Full Text] [Related]
20. Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up.
Liu Z; Peng Y; Li J; Lu H; Peng L; Zhou J; Zhou S; Huang C; Wang M; Zhu L; Chen H; Wang L; Fei Y; Zhao Y; Zeng X; Zhang W
J Intern Med; 2022 Jul; 292(1):91-102. PubMed ID: 35419810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
